The personal utility outcomes of the IMPACT-AD BC study have now been peer-reviewed and published in one of the leading journals in the...

Findings from the IMPACT-AD BC study.

A major success of the Canadian IMPACT-AD study was the launch, in 2021, of the national Alzheimer's disease biomarker testing program....

IMPACT-AD study investigator Dr. Robin Hsiung talks about frontotemporal dementia on the Global TV News Health Matters series....

Dementia Dialogue

Join us January 25, 2023 at 2 pm pacific time for a webinar on Alzheimer's disease biomarker testing hosted by the Alzheimer Society of...

Talking with podcaster Real Talk Ryan Jespersen about the new Canadian Alzheimer's disease biomarker testing program based at St. Paul's...

On July 1, 2021 the St. Paul's Hospital Clinical Laboratory in Vancouver launched the Alzheimer's disease biomarker testing program for...

Want to learn more about the biomarkers involved in Alzheimer's disease testing, and how cerebrospinal fluid is collected? Check out our...

The IMPACT-AD team's Alzheimer's disease testing innovation for amyloid-beta proteoforms has been published in a leading scientific...

At the 2020 Alzheimer Update, Dr. DeMarco and Dr. Hsiung discuss biomarker testing and therapies for Alzheimer's disease....

"A diagnosis explains what's happening, why you're not remembering" In this interview, Dr. Stites talks about reducing the stigma around...

The Alzheimer Society of British Columbia interviews Dr. DeMarco about the development of diagnostic tests for Alzheimer's....

The IMPACT-AD ("Translating research into practice: Investigating the impact of Alzheimer's disease diagnostics in Canada") Study was...